CD19 and acute myeloid leukemia: CAR T cells were mainly produced from patients with ALL and non-Hodgkin’s lymphoma (NHL), but also from patients with r/r Richter’s transformation and CD19 positive acute myeloid leukemia (AML) (10, 14–16).